Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H9NO3 |
Molecular Weight | 143.1406 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)OC(C)(C)C1=O
InChI
InChIKey=IRYJRGCIQBGHIV-UHFFFAOYSA-N
InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3
Molecular Formula | C6H9NO3 |
Molecular Weight | 143.1406 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Trimethadione (brand name is TRIDIONE) is an oxazolidinedione compound that was developed as an antiepileptic agent for control of petit mal seizures that are refractory to treatment with other drugs. Tridione does not modify the maximal seizure pattern in patients undergoing electroconvulsive therapy and has a sedative effect that may increase to the point of ataxia when excessive doses are used. Trimethadione acts as a voltage-activated T-type Ca2+ channel blocker. Trimethadione is rapidly absorbed from the gastrointestinal tract. It is demethylated by liver microsomes to the active metabolite, dimethadione. Approximately 3% of a daily dose of tridione is recovered in the urine as the unchanged drug. The majority of trimethadione is excreted slowly by the kidney in the form of dimethadione.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362995 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16171802 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TRIDIONE Approved UseINDICATIONS TRIDIONE (trimethadione) is indicated for the control of petit mal seizures that are refractory to treatment with other drugs. Launch Date-7.5530882E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8441739/ |
4 mg/kg single, oral dose: 4 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRIMETHADIONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
148 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8441739/ |
4 mg/kg single, oral dose: 4 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRIMETHADIONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8441739/ |
4 mg/kg single, oral dose: 4 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRIMETHADIONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
150 mg 4 times / day multiple, oral Dose: 150 mg, 4 times / day Route: oral Route: multiple Dose: 150 mg, 4 times / day Co-administed with:: phenobarbital(15 mg. four times daily.) Sources: |
unhealthy, 16 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 16 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hepatitis... AEs leading to discontinuation/dose reduction: Hepatitis (1 patient) Sources: |
0.3 g 3 times / day multiple, oral (starting) Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Co-administed with:: phénobarbital(4 grains (0.25 Gm.) daily) Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 23 years Sex: F Population Size: 1 Sources: |
Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: |
0.3 g 3 times / day multiple, oral (starting) Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 23 years Sex: F Population Size: 1 Sources: |
Disc. AE: Agranulocytosis, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Agranulocytosis (grade 5, 1 patient) Sources: Thrombocytopenia (grade 5, 1 patient) |
24 g 1 times / day multiple, oral Studied dose Dose: 24 g, 1 times / day Route: oral Route: multiple Dose: 24 g, 1 times / day Sources: |
unhealthy n = 1 Health Status: unhealthy Condition: tetanus Sex: M Population Size: 1 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hepatitis | 1 patient Disc. AE |
150 mg 4 times / day multiple, oral Dose: 150 mg, 4 times / day Route: oral Route: multiple Dose: 150 mg, 4 times / day Co-administed with:: phenobarbital(15 mg. four times daily.) Sources: |
unhealthy, 16 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 16 years Sex: M Population Size: 1 Sources: |
Aplastic anemia | grade 5, 1 patient Disc. AE |
0.3 g 3 times / day multiple, oral (starting) Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Co-administed with:: phénobarbital(4 grains (0.25 Gm.) daily) Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 23 years Sex: F Population Size: 1 Sources: |
Agranulocytosis | grade 5, 1 patient Disc. AE |
0.3 g 3 times / day multiple, oral (starting) Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 23 years Sex: F Population Size: 1 Sources: |
Thrombocytopenia | grade 5, 1 patient Disc. AE |
0.3 g 3 times / day multiple, oral (starting) Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: petit mal seizures Age Group: 23 years Sex: F Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive | ||||
Page: 7.0 |
likely | |||
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Nephrotic syndrome caused by probenecid. | 1967 Jan 2 |
|
Possible teratogenicity of trimethadione and paramethadione. | 1970 Aug 1 |
|
Fetal anomalies following maternal trimethadione ingestion. | 1973 May |
|
Di-n-propylacetic acid--profile of anticonvulsant activity in mice. | 1976 Feb |
|
Measurement of anticonvulsant activity in the Papio papio model of epilepsy. | 1976 Sep |
|
[Quantitative analysis of conditional-optimal doses of succilep and trimetin in the treatment of children and adolescents with minor forms of epilepsy]. | 1977 |
|
Anti-convulsant effect of phthalazino-2,3b-phthalazine-5(14H),12(7h)-dione (L-5418). I. Behavioral effect. | 1978 Feb |
|
Phenotypic malformations in association with maternal trimethadione therapy. | 1978 Feb |
|
Anticonvulsants specific for petit mal antagonize epileptogenic effect of leucine enkephalin. | 1980 Nov 28 |
|
Comparison of the actions of trimethadione and chlordiazepoxide in animal models of anxiety and benzodiazepine receptor binding. | 1982 Nov |
|
A model of chronic spontaneous petit mal-like seizures in the rat: comparison with pentylenetetrazol-induced seizures. | 1984 Jun |
|
Antiepileptic drug evaluation in a new animal model: spontaneous petit mal epilepsy in the rat. | 1985 |
|
Fetal anticonvulsant syndrome in rats: effects on postnatal behavior and brain amino acid content. | 1985 Sep-Oct |
|
Only certain antiepileptic drugs prevent seizures induced by pilocarpine. | 1987 Jul |
|
Anticonvulsive and convulsive effects of lidocaine: comparison with those of phenytoin, and implications for mechanism of action concepts. | 1988 Sep |
|
Effects of antiepileptic drugs on absence-like and tonic seizures in the spontaneously epileptic rat, a double mutant rat. | 1988 Sep-Oct |
|
Effects of the oxazolidinedione anticonvulsants trimethadione and dimethadione and the barbiturate homolog 5,5-dimethylbarbituric acid on N-nitrosodiethylamine-initiated renal and hepatic carcinogenesis in the F344/NCr rat. | 1992 |
|
Dissolution of pancreatic stones by oral trimethadione in patients with chronic calcific pancreatitis. | 1994 Sep-Oct |
|
Characterization of the antiabsence effects of SCH 50911, a GABA-B receptor antagonist, in the lethargic mouse, gamma-hydroxybutyrate, and pentylenetetrazole models. | 1995 Sep |
|
Anticonvulsants for soman-induced seizure activity. | 1999 Mar-Apr |
|
[Fetal trimethadione syndrome]. | 2001 |
|
The clinical importance of the trimethadione tolerance test as a method for quantitative assessment of hepatic functional reserve in patients with biliary atresia. | 2001 Dec |
|
Determination of trimetazidine HCl by adsorptive stripping square-wave voltammetry at a glassy carbon electrode. | 2002 Jan 1 |
|
Postnatal closure of membranous ventricular septal defects in Sprague-Dawley rat pups after maternal exposure with trimethadione. | 2004 Jun |
|
The history of barbiturates a century after their clinical introduction. | 2005 Dec |
|
The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. | 2005 Oct 3 |
|
Effects of anticonvulsant drugs on life span. | 2006 Apr |
|
The ethics of excluding women who become pregnant while participating in clinical trials of anti-epileptic medications. | 2006 Dec |
|
Pharmacology of delayed aging and extended lifespan of Caenorhabditis elegans. | 2006 Oct |
|
Education and imaging. Hepatobiliary and pancreatic: oral therapy for pancreatic duct stones. | 2006 Sep |
|
Classification and diagnosis of ear malformations. | 2007 |
|
Treatment of Lennox-Gastaut syndrome: overview and recent findings. | 2008 Dec |
|
The anticonvulsant ethosuximide disrupts sensory function to extend C. elegans lifespan. | 2008 Oct |
|
Neuroprotective effects of blockers for T-type calcium channels. | 2009 Oct 28 |
|
Lamotrigine extends lifespan but compromises health span in Drosophila melanogaster. | 2010 Feb |
|
Allyl isothiocyanate that induces GST and UGT expression confers oxidative stress resistance on C. elegans, as demonstrated by nematode biosensor. | 2010 Feb 17 |
|
Zebrafish (Danio rerio) embryos as a model for testing proteratogens. | 2011 Mar 15 |
Patents
Sample Use Guides
Usual Adult Dosage: 0.9-2.4 grams daily in 3 or 4 equally divided doses (i.e., 300−600 mg 3 or 4 times daily). Initially, give 0.9 gram daily; increase this dose by 300 mg at weekly intervals until therapeutic results are seen or until toxic symptoms appear.
Children's Dosage: Usually 0.3-0.9 gram daily in 3 or 4 equally divided doses.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:39:45 UTC 2023
by
admin
on
Wed Jul 05 22:39:45 UTC 2023
|
Record UNII |
R7GV3H6FQ4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000008486
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
||
|
WHO-ATC |
N03AC02
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
||
|
NDF-RT |
N0000175753
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
||
|
WHO-VATC |
QN03AC02
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2751
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
7316
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
100000076924
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
D014293
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
5576
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
TRIMETHADIONE
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | Description: Colourless, granular crystals; odour, slightly camphoraceous. Solubility: Soluble in water; freely soluble in ethanol (~750 g/l) TS and ether R. Category: Anticonvulsant. Storage: Trimethadione should be kept in a well-closed container. Definition: Trimethadione contains not less than 98.0% and not more than 101.0% of C6H9NO3, calculated with reference to the dried substance. | ||
|
1714
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
SUB11307MIG
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
127-48-0
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
169503
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
15799
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
DTXSID9021396
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
Trimethadione
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
R7GV3H6FQ4
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
10827
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | RxNorm | ||
|
204-845-8
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
M11145
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB00347
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
C47772
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY | |||
|
CHEMBL695
Created by
admin on Wed Jul 05 22:39:45 UTC 2023 , Edited by admin on Wed Jul 05 22:39:45 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
Dimethadione has anticonvulsant activity and has been used clinically in the treatment of petit mal epilepsy.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |